Effects of high mobility group protein box 1 and toll like receptor 4 pathway on warts caused by human papillomavirus

Molecular Medicine Reports

Volumn 10, Issue 4, 2014, Pages 1765-1771

  Weng, Hui ^a,b   Liu, Hongbo ^b   Deng, Yunhua ^b   Xie, Yuyan ^a   Shen, Guanxin ^b  

^a SUN YAT SEN UNIVERSITY   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Condyloma acuminatum; High mobility group protein box 1; Inflammation; Nuclear factor B; Toll like receptor 4; Verruca vulgaris

Indexed keywords

HIGH MOBILITY GROUP B1 PROTEIN; TLR4 PROTEIN, HUMAN; TOLL LIKE RECEPTOR 4; TRANSCRIPTION FACTOR RELA;

CELL NUCLEUS; EXTRACELLULAR SPACE; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; PAPILLOMAVIRIDAE; PATHOGENICITY; PATHOLOGY; VERRUCA VULGARIS;

CELL NUCLEUS; EXTRACELLULAR SPACE; HMGB1 PROTEIN; HUMANS; IMMUNOHISTOCHEMISTRY; PAPILLOMAVIRIDAE; TOLL-LIKE RECEPTOR 4; TRANSCRIPTION FACTOR RELA; WARTS;

EID: 84924220081     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2014.2477     Document Type: Article

References (26)

1. Bernard HU, Burk RD, Chen Z, van Doorslaer K, zur Hausen H and de Villiers EM: Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology 401: 70-79, 2010.
2. Stanley MA, Pett MR and Coleman N: HPV: from infection to cancer. Biochem Soc Trans 35: 1456-1460, 2007.
3. Aggarwal BB, Shishodia S, Sandur SK, Pandey MK and Sethi G: Inflammation and cancer: how hot is the link? Biochem Pharmacol 72: 1605-1621, 2006. (Pubitemid 44666739)
4. Balkwill F and Coussens LM: Cancer: an inflammatory link. Nature 431: 405-406, 2004. (Pubitemid 39329565)
5. Thomas JO and Travers AA: HMG1 and 2, and related 'architectural' DNA-binding proteins. Trends Biochem Sci 26: 167-174, 2001. (Pubitemid 32197576)
6. Tadie J, Bae HB, Deshane J, et al: Toll-like receptor 4 engagement inhibits adenosine 5′-monophosphate-activated protein kinase activation through a high mobility group box 1 protein-dependent mechanism. Mol Med 18: 659-668, 2012.
7. Dai S, Sodhi C, Cetin S, et al: Extracellular high mobility group box-1 (HMGB1) inhibits enterocyte migration via activation of Toll-like receptor-4 and increased cell-matrix adhesiveness. J Biol Chem 285: 4995-5002, 2010.
8. Naugler WE and Karin M: NF-kappaB and cancer-identifying targets and mechanisms. Curr Opin Genet Dev 18: 19-26, 2008.
9. Fiuza C, Bustin M, Talwar S, et al: Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood 101: 2652-2660, 2003. (Pubitemid 36857626)
10. Poser I, Golob M, Buettner R and Bosserhoff AK: Upregulation of HMG1 leads to melanoma inhibitory activity expression in malignant melanoma cells and contributes to their malignancy phenotype. Mol Cell Biol 23: 2991-2998, 2003. (Pubitemid 36403094)
11. Weng H, Deng Y, Xie Y, Liu H and Gong F: Expression and significance of HMGB1, TLR4 and NF-κB p65 in human epidermal tumors. BMC Cancer 13: 311, 2013.
12. Frazer IH: Interaction of human papillomaviruses with the host immune s ystem: a w ell e volved r elationship. V irology 384: 410-414, 2009.
13. Scott M, Nakagawa M and Moscicki AB: Cell-mediated immune response to human papillomavirus infection. Clin Diagn Lab Immunol 8: 209-220, 2001. (Pubitemid 32217046)
14. Gröne A: Keratinocytes and cytokines. Vet Immunol Immunopathol 88: 1-12, 2002.
15. Locksley RM, Killeen N and Lenardo MJ: The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 104: 487-501, 2001. (Pubitemid 32201945)
16. Vaccari T, Beltrame M, Ferrari S and Bianchi ME: Hmg4, a new member of the Hmg1/2 gene family. Genomics 49: 247-252, 1998. (Pubitemid 28240691)
17. Zeh HJ III and Lotze MT: Addicted to death: invasive cancer and the immune response to unscheduled cell death. J Immunother 28: 1-9, 2005.
18. Ulloa L and Messmer D: High-mobility group box 1 (HMGB1) protein: friend and foe. Cytokine Growth Factor Rev 17: 189-201, 2006. (Pubitemid 43949075)
19. Kim SW, Lim CM, Kim JB, et al: Extracellular HMGB1 released by NMDA treatment confers neuronal apoptosis via RAGE-p38 MAPK/ERK signaling pathway. Neurotox Res 20: 159-169, 2011.
20. Nogueira-Machado JA, Volpe CM, Veloso CA and Chaves MM: HMGB1, TLR and RAGE: a functional tripod that leads to diabetic inflammation. Expert Opin Ther Targets 15: 1023-1035, 2011.
21. Kawai T and Akira S: The roles of TLRs, RLRs and NLRs in pathogen recognition. Int Immunol 21: 317-337, 2009.
22. Hasan UA, Bates E, Takeshita F, et al: TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16. J Immunol 178: 3186-3197, 2007. (Pubitemid 46333201)
23. Verma IM, Stevenson JK, Schwarz EM, Van Antwerp D and Miyamoto S: Rel/NF-kappa B/I kappa B family: intimate tales of association and dissociation. Genes Dev 9: 2723-2735, 1995. (Pubitemid 3009952)
24. Ghosh S, May MJ and Kopp EB: NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 16: 225-260, 1998. (Pubitemid 28183365)
25. Ghosh S and Hayden MS: New regulators of NF-kappaB in inflammation. Nat Rev Immunol 8: 837-848, 2008.
26. Karin M and Greten FR: NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 5: 749-759, 2005. (Pubitemid 41400849)